Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Igor Diemberger

Showing results (21-30 of 238) with videos related to

Pageof 24
Sort By:
Heart (British Cardiac Society)|December 4, 2012
Cost-effectiveness of cardiac resynchronisation therapyGiuseppe Boriani, Igor Diemberger, Mauro Biffi, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Clinical Therapeutics|November 20, 2025
Response to: Letter to the Editor Regarding "Real-World Polypharmacy and Drug-Drug Interactions in a Large Cohort of Direct Oral Anticoagulant Users With Atrial Fibrillation"Veronica De Angelis, Maria Carelli, Alberto Spadotto, et al.
Internal and Emergency Medicine|April 27, 2018
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' replyEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Internal and Emergency Medicine|September 25, 2017
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectationsEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2026
Major Adverse Cardiac Events with Ondansetron: The Role of Observational Evidence to Inform Actionable Safer Prescribing in Cardio-OncologyEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Cardiovascular Diagnosis and Therapy|September 15, 2018
Leadless left ventricular endocardial pacing: a real alternative or a luxury for a few?Elia De Maria, Matteo Ziacchi, Igor Diemberger, et al.
International Journal of Molecular Sciences|April 13, 2023
Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation, Heart Failure, and Amyloidosis of the AtriaFarzad Rahbar Kouibaran, Mario Sabatino, Chiara Barozzi, et al.
Pageof 24

Showing results (21-30 of 238) with videos related to

Sort By:
Pageof 24
Heart (British Cardiac Society)|December 4, 2012
Cost-effectiveness of cardiac resynchronisation therapyGiuseppe Boriani, Igor Diemberger, Mauro Biffi, et al.
Drug Safety|February 24, 2021
Authors' Reply to Robert P. Giugliano and Colleagues' Comment on: "Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance"Emanuel Raschi, Michele Fusaroli, Igor Diemberger, et al.
Drug Safety|April 9, 2017
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical PracticeElisabetta Poluzzi, Emanuel Raschi, Igor Diemberger, et al.
Clinical Therapeutics|November 20, 2025
Response to: Letter to the Editor Regarding "Real-World Polypharmacy and Drug-Drug Interactions in a Large Cohort of Direct Oral Anticoagulant Users With Atrial Fibrillation"Veronica De Angelis, Maria Carelli, Alberto Spadotto, et al.
Internal and Emergency Medicine|April 27, 2018
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations-authors' replyEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Internal and Emergency Medicine|September 25, 2017
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectationsEmanuel Raschi, Igor Diemberger, Benilde Cosmi, et al.
Clinical Pharmacology and Therapeutics|June 5, 2026
Major Adverse Cardiac Events with Ondansetron: The Role of Observational Evidence to Inform Actionable Safer Prescribing in Cardio-OncologyEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Lancet (London, England)|August 14, 2018
Reporting of immune checkpoint inhibitor-associated myocarditisEmanuel Raschi, Igor Diemberger, Elisabetta Poluzzi, et al.
Cardiovascular Diagnosis and Therapy|September 15, 2018
Leadless left ventricular endocardial pacing: a real alternative or a luxury for a few?Elia De Maria, Matteo Ziacchi, Igor Diemberger, et al.
International Journal of Molecular Sciences|April 13, 2023
Atrial Natriuretic Peptides as a Bridge between Atrial Fibrillation, Heart Failure, and Amyloidosis of the AtriaFarzad Rahbar Kouibaran, Mario Sabatino, Chiara Barozzi, et al.
Pageof 24